BREYANZI

This brand name is authorized in Estonia, Croatia, Lithuania, Poland, United States

Active ingredients

The drug BREYANZI contains one active pharmaceutical ingredient (API):

1 Lisocabtagene maraleucel UNII 7K2YOJ14X0 - LISOCABTAGENE MARALEUCEL

Lisocabtagene maraleucel is a CD19-directed genetically modified autologous cellular immunotherapy administered as a defined composition to reduce variability in CD8+ and CD4+ T-cell dose. CAR binding to CD19 expressed on the cell surface of tumour and normal B cells induces activation and proliferation of CAR T cells, release of pro-inflammatory cytokines, and cytotoxic killing of target cells. Read about Lisocabtagene maraleucel

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BREYANZI Dispersion for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XL08		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1880737
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094513
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100468788
Country: US	FDA, National Drug Code	Identifier(s): 73153-900, 73153-901, 73153-902